MS
ADAP

Maven Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

Maven Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-225,000
Closed -$2.25M – 591
2020
Q2 		$2.25M Buy
+225,000
New +$1.41M 0.15% 123
2020
Q1 		– Sell
-150,000
Closed -$185K – 299
2019
Q4 		$185K Buy
+150,000
New +$160K 0.02% 347

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Maven Securities's ADAP Position: Q3 2020 in Review

Maven Securities sold out of Adaptimmune Therapeutics (ADAP) in Q3 2020, closing a stake of 225,000 shares — an estimated $2.25M sold.

Maven Securities first reported a position in ADAP in Q4 2019 and held it in 2 quarters. The position peaked at $2.25M in Q2 2020. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2020.

  • Maven Securities reported no remaining Adaptimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Maven Securities sold 225,000 Adaptimmune Therapeutics shares in Q3 2020, an estimated $2.25M.
  • Maven Securities first reported a position in Adaptimmune Therapeutics in Q4 2019 and held it in 2 quarters.
  • Maven Securities's Adaptimmune Therapeutics position peaked at $2.25M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2020.

Based on Maven Securities's 13F filing for Q3 2020, filed 13 Nov 2020.